Prediction Case File
YouTubeTracking Live

Oracle Stock: The Market Is Missing Something BIG!

1 extracted signal · 0 resolved · 1 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
03 Nov 2026, 18:48 UTC
Recorded by Tahlil Plus
03 Nov 2026, 22:00 UTC
Video preview for Oracle Stock: The Market Is Missing Something BIG!
Source overview

AI-generated source summary

Oracle's financial projections suggest a strong turnaround potential, despite recent stock price declines and a BBB-/A-3 S&P rating. The company forecasts significant growth in total revenues, aiming for over $225 billion by FY30. Key metrics include a projected non-GAAP EPS of $21.00+ and a 40%+ non-GAAP operating margin by FY30. Oracle expects to be fully funded and self-funded by FY28, with free cash flow projected at $30 billion plus by FY29, avoiding further debt issuance. The company's business model, focused on large contract RPO conversion to revenue, shows a positive trend with increasing quarterly revenues and a healthy 5-year average contract duration. Despite a high interest expense, the maturity of debt is well-spread, and low interest rates on borrowings mitigate immediate risk. The primary credit risk identified is Oracle's reliance on OpenAI, which accounts for roughly half of its RPO. However, the company's ability to generate significant future free cash flow and its potential for high ROI (28%) position it attractively for investors with a high risk tolerance.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Tracking Live
Signals
1
Extracted from this source
Open
1
Still being tracked
Successful
0
Resolved successfully
Failed
0
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
—
0 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  5. Source processing completed

    Source analysis and structured extraction completed.

  6. Live evaluation in progress

    1 signal remains active.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.9
Tracked signals
355
Historical success
34.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail